Elevar Therapeutics
is a Utah-based biopharmaceutical company that develops and commercializes medicines to treat a range of diseases... Read moreElevar Therapeutics
is a Utah-based biopharmaceutical company that develops and commercializes medicines to treat a range of diseases... Read more
News
Jan 27, 2025
StreetInsider
Press Release: Elevar Therapeutics : Elevar Therapeutics Announces the Formation and Members of Scientific Advisory Board
Jan 24, 2025
Benzinga
Elevar Therapeutics: Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in Hepatocellular Carcinoma
Dec 11, 2024
Marketscreener
Elevar Therapeutics: Relay Therapeutics Signs Global Licensing Deal With Elevar Therapeutics for Lirafugratinib
Oct 31, 2024
Korea Biomedical Review
Elevar Therapeutics: FDA regulations evolve as science changes: Elevar Therapeutics COO
Oct 23, 2024
Medthority
Elevar Therapeutics: NDA resubmitted to FDA for rivoceranib + camrelizumab as first-line systemic treatment for unresectable or metastatic hepatocellular carcinoma
Sep 12, 2024
GlobeNewswire
Press Release: Elevar Therapeutics : Elevar Therapeutics Reports Advances in HCC and Other Oncology Clinical Programs for Rivoceranib Plus Camrelizumab at the European Society for Medical Oncology Congress 2024
Aug 01, 2024
GlobalNewswire
Press Release: Elevar Therapeutics : Elevar Therapeutics Granted Orphan Medicinal Product Designation by the European Medicines Agency for First-Line Systemic Therapy for Unresectable Hepatocellular Carcinoma
May 30, 2024
StreetInsider
Press Release: Elevar Therapeutics : Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma
Jan 18, 2024
GlobalNewswire
Press Release: Elevar Therapeutics : Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study at 2024 ASCO Gastrointestinal Cancers Symposium
Nov 23, 2023
Marketscreener
Elevar Therapeutics: Vivesto AB and Elevar Therapeutics Inc. Sign Agreement Ending Apealea? Partnership
